Product category:
Cell/tissue handling and counting
News Release from: Guava Technologies | Subject: EZCD4 System
Edited by the Laboratorytalk Editorial
Team on 16 May 2006
FDA 510(k) clearance of EZCD4 for CD4
Monitoring
Guava Technologies has received 510(k) clearance from the US FDA for the EZCD4, which includes the EZCD4 Assay, the PCA Instrument and CytoSoft v2.3 software, incorporating three modules
Guava Technologies, a developer of cost-effective and accessible cell-analysis systems for life science research, drug discovery, development and clinical diagnostics, today announced that Guava has received 510(k) clearance from the US Food and Drug Administration for the Guava EZCD4 System, which includes the EZCD4 Assay, the PCA Instrument and CytoSoft v2.3 software, incorporating three modules (EZCD4, Guava Check and Clean and Shutdown) The EZCD4 System is intended to identify and quantify absolute counts of CD4+ T-lymphocytes in EDTA whole blood
This article was originally published on Laboratorytalk on 23 Jun 2008 at 8.00am (UK)
Related stories
Simple detection of early and late apoptosis
The newly revised Guava Nexin Assay conveniently provides all necessary reagent components in a single cocktail to minimise assay steps, assay time and possible sources of contamination
CD4 monitoring for adult, paediatric measurements
Guava Technologies has announced a complete turnkey package for CD4 monitoring that requires minimum technical expertise to operate and obtain high quality results
Utilising Guava's easy-to-use and cost-effective microcapillary cytometry technology, the Guava EZCD4 system is intended for the ongoing monitoring of patients with documented diagnosis of an immunodeficiency disease.
Absolute counts of CD4+ T-cells can be useful in characterising, monitoring and evaluating the effectiveness of treatment for autoimmune and immunodeficiency diseases.
Determining the number of CD4+ T-cells can be useful in monitoring human immunodeficiency virus (HIV)-infected individuals.
Further reading
Antibody characterisation now more comprehensive
Guava Technologies says it provides new levels of flexibility and analysis with its RapidQuant IgG Assays for quantification of mouse and human antibodies
Easier determination of cell cycle phases
Enhanced version of Guava Cell Cycle Assay allows quick, easy determinations of G0/G1, S and G2/M cell cycle phases and distinguishes without interference commonly occuring aggregates
Quantification of IgG antibodies becomes faster
Guava Technologies has launched a new and enhanced version of the company's Guava RapidQuant IgG Antibody Quantification Assays for mouse and human antibodies
The Guava EZCD4 Assay is a two-colour, direct immunofluorescence reagent kit intended for use with a Guava PCA System.
The kit consists of a monoclonal anti-human CD3 antibody that uniquely identifies T-cells and a monoclonal anti-human CD4 antibody that allows the identification of human helper/inducer CD4+ T-cells (HLA Class II reactive).
Lawrence Bruder, Guava Technologies's chief executive officer, stated: "It is an important milestone for Guava to receive FDA clearance on the EZCD4 assay system based on our proprietary microcapillary cytometry technology".
"This enabling technology provides our customers with reliable and robust measurements using smaller samples and fewer reagents than other systems in the market".
"In addition to the very necessary diagnostic application of monitoring immuno-compromised patients, we believe the Guava system provides an ideal approach for combining powerful cell analysis with healthcare systems struggling to conserve resources in personnel and equipment." Guava Technologies's microcapillary cytometry technology enables the EZCD4 system to be highly compact, portable and low maintenance.
Testing requires only 10microlitres of whole blood per patient.
The Guava EZCD4 also requires far less reagent per sample, dramatically lowering the overall costs of performing the assay.
Moreover, the microcapillary technology does not require the use of sheath fluid, large amounts of which are typically needed for conventional flow cytometers.
The elimination of sheath fluid results in less bio-hazardous waste and further reduces the running costs of the system.
Daily maintenance is minimal, requiring a short clean and shutdown procedure performed at the end of each day.
"We are very excited about the FDA clearance as this validates the capabilities of our technology," said Lalit Dhir, Guava Technologies's VP of corporate development and strategic marketing.
"This will allow us to work with partners who are interested in leveraging our platform's unique advantages of ease of use and smaller sample requirements for the development of breakthrough diagnostics for a wide variety of clinical applications".
Guava Technologies, a privately held biotechnology company, is the leading provider of on-demand, easy-to-use single cell analysis systems.
Guava Personal Cell Analysis (PCA) systems, including the Guava PCA, Guava PCA-96 and Guava EasyCyte systems, are integrated, fully optimised, microcapillary cytometry systems with embedded absolute cell counting capability.
Used worldwide by the life sciences, biotechnology, and pharmaceutical industries, as well as clinical testing institutions (outside the United States and Europe), Guava's products have broad applications in scientific research and throughout the drug discovery and lead optimisation process, as well as for cell counting and optimisation of commercial biopharmaceutical production.
Guava offers a variety of assays and dedicated software modules for the Guava PCA systems, enhancing the system's overall ease-of-use.
• Guava Technologies: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
